<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437526</url>
  </required_header>
  <id_info>
    <org_study_id>15-001678</org_study_id>
    <nct_id>NCT02437526</nct_id>
  </id_info>
  <brief_title>Analytic Treatment Interruption (ATI) to Assess HIV Cure</brief_title>
  <official_title>Analytic Treatment Interruption of Antiretroviral Therapy to Assess for HIV Cure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine if individual patients with HIV infection have been cured&#xD;
      of the infection. To do this, antiretroviral therapy is discontinued under close medical&#xD;
      supervision and the patient monitored over time for reactivation of infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to virologic rebound</measure>
    <time_frame>38 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to HIV-1 RNA ≥ 20 copies/ml</measure>
    <time_frame>38 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HIV-1 RNA ≥ 100 copies/ml</measure>
    <time_frame>38 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Treatment interruption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antiretroviral therapy will be discontinued under close laboratory monitoring and clinical supervision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Analytic treatment interruption</intervention_name>
    <arm_group_label>Treatment interruption</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  HIV-1 infected with the potential to have been cured of infection in the course of&#xD;
             routine clinical care in the opinion of the treating physician and study team&#xD;
&#xD;
          -  Have an undetectable plasma HIV-1 RNA and undetectable proviral DNA on suppressive&#xD;
             antiretroviral therapy on at least two consecutive measures for at least 6 months&#xD;
&#xD;
          -  Able and willing to either abstain from sexual activity or use barrier contraceptives&#xD;
             during the ATI&#xD;
&#xD;
          -  Negative serum β-HCG pregnancy test in women with childbearing potential&#xD;
&#xD;
          -  Have the ability to give appropriate informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  Women who can become pregnant who are unable or unwilling to use both barrier and&#xD;
             pharmacologic contraceptives during the ATI&#xD;
&#xD;
          -  Previous or current infections that are at high risk of reactivating with immune&#xD;
             suppression, in whom there are no effective antimicrobial prophylaxis options&#xD;
&#xD;
          -  Advanced cardiopulmonary or liver disease&#xD;
&#xD;
          -  History of untreated solid or hematologic malignancies&#xD;
&#xD;
          -  Evidence of active viral replication in patients co-infected with Hepatitis B virus&#xD;
             (HBV). Treatment should be provided to suppress HBV replication with agents that do&#xD;
             not have activity against HIV (ie entecavir) prior to consideration for ATI.&#xD;
&#xD;
          -  Evidence of viral replication with Hepatitis C virus (HCV), together with evidence of&#xD;
             any hepatic fibrosis or inflammation. Such patients should be offered HCV treatment&#xD;
             first.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Badley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Andrew D. Badley, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cure</keyword>
  <keyword>Analytic treatment interruption</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

